Phase 2 Chronic Fatigue Syndrome Trial, Recruiting NCT07627815 Sponsor: ParagonClinicals Inc. Condition: Chronic Fatigue Syndrome
Back to Chronic Fatigue Syndrome

Phase 2 Chronic Fatigue Syndrome Trial, Recruiting

NCT07627815
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 19 years of age or older.
  • You tested negative for COVID-19 at least 4 weeks before joining the study.
  • You were previously confirmed to have had COVID-19 (by a lab test or doctor's diagnosis) more than 4 weeks before joining the study.
  • You have been diagnosed with Long COVID, meaning you developed or still have symptoms 3 months after your COVID-19 infection, and those symptoms have lasted more than 2 months with no other known cause.
  • If you are a woman who could become pregnant: you have a negative pregnancy test and are willing to use an approved form of birth control throughout the study (if you become pregnant during the study, you must stop taking the study products immediately and tell the study team).
  • You are willing to stop taking any over-the-counter supplements, vitamins, or natural health products during the study, as well as any other prohibited medications.
  • You are willing to avoid medications that could directly affect fatigue or mental focus during the study.
  • You are willing to follow the study's diet and exercise recommendations as best you can.
  • You are willing to complete a walking test (a 6-minute walk test).
  • You are willing to fill out questionnaires and keep a diary as part of the study.
  • You are able to give your own consent, or have a legal representative who can do so on your behalf.

Who may not be able to join:

  • You are currently pregnant, breastfeeding, or trying to become pregnant.
  • You follow a vegetarian diet or are unable to follow the study's dietary guidelines.
  • You have a known allergy or sensitivity to the study product (called PNMR) or any of its ingredients.
  • You are currently taking part in another drug clinical trial (participation in some COVID-19 antiviral trials may be allowed with sponsor approval — confirm with trial site).
  • The study doctor believes that your participation could put your health at risk.
  • You have taken high-dose Vitamin D (5,000 IU per day or more) and/or high-dose Zinc (50mg per day without copper) every day for 4 or more weeks in a row within the 4 weeks before starting the study.
  • You take medications or treatments that do not mix safely with the study product (confirm with trial site).
  • You are unable to swallow a larger number of capsules.
  • The study doctor believes that your participation could affect the study results or prevent you from completing the study.
  • You have a health condition that makes Vitamin D3 unsafe for you, including: a known allergy to Vitamin D or related products; too much calcium in your blood or urine; kidney stones; severely reduced kidney function; difficulty absorbing nutrients from food; unusual sensitivity to the effects of Vitamin D; a condition called sarcoidosis; or already having too much Vitamin D in your body.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Sam Bock, BA Environmental Science, ParagonClinicals Inc CEO / CSO

Phone: 514 998-3935

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
ParagonClinicals Inc.
Registry
ClinicalTrials.gov
Start date
20 May 2026
Est. completion
26 August 2026

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Change in distance walked on the 6-minute walk test (6MWT) after 6 weeks of treatment.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov